Genscript Expects to Swing to H1 Profit

MT Newswires Live
Jul 22

Genscript Biotech (HKG:1548) expects to swing to profit in the first half of 2025, according to a Hong Kong bourse filing Tuesday.

The biopharmaceutical company is estimating $175.4 million to $204.6 million in profit before tax, compared to a loss of $127.9 million in the year-ago period.

Genscript expects to post its financial results by the end of August.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10